1 min read
Add as a preferred source on Google

Palatin Targets First-Half 2027 Start for Lead Lipidated MC4R Peptide

Fiscal 2027 first-quarter priorities included IND-enabling activities for the peptide and development of oral small-molecule candidates.

No image assigned because the earnings figure repeats earlier coverage / TokenPost.ai
No image assigned because the earnings figure repeats earlier coverage / TokenPost.ai

Palatin Technologies, Inc. is targeting a Phase 1 study of its lead lipidated MC4R peptide in the first half of calendar 2027, while advancing work on oral candidates in its drug-development programs.

The company’s fiscal 2027 first-quarter priorities included IND-enabling activities for the peptide and development of oral small-molecule candidates.

Palatin is targeting the study for the first half of calendar 2027. The update describes work on the peptide as ongoing.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…